It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Incidence of liver cancer as one of the most common cancers worldwide and become the significant contributor for the mortality among cancer patients. The disease burden, risk factors, and trends in incidence and mortality of liver cancer globally was described subsequently estimated the projections of liver cancer incidence or mortality by 2040. Data regarding age-standardized incidence and mortality rates for liver cancer was obtained from multiple databases, including GLOBOCAN 2020, CI5 volumes I–XI, WHO mortality database, and Global Burden of Disease (GBD)-2019. Concentrating on worldwide variations, this thorough analysis offers insights into patterns of incidence and mortality based on gender and age. Our findings encompass significant indicators, including age-standardized rates (ASRs), average annual percentage change (AAPC), and future projections extending up to the year 2040. Liver cancer holds the sixth position in terms of most frequently diagnosed cancers and stands as the sixth leading cause of cancer-related deaths worldwide in 2020, accounting for 905,677 new cases and 782,000 fatalities. Additionally, liver cancer contributed to 12,528,421 age-standardized disability-adjusted life years (DALYs), with an age-standardized DALYs rate of 161.92 in 2019 worldwide. The age-specific incidence rates exhibited significant variations across different regions, showing a fivefold difference in males and females. A significant increase in incidence was observed in North Europe and Asia, while North African countries reported a higher mortality burden (ASR, 10 per 100,000) compared to developed countries. Since last few years, the incidence and mortality rates have increased and attained Annual Average Percentage Change (AAPC) incidence rate of 7.7 (95% CI 3.9–11.6) for men and the highest AAPC mortality rate of 12.2 (95% CI 9.5–15.0) for women. In 2019, Western Europe emerged as the high-risk region for DALYs related to smoking and alcohol consumption, while high-income North America carried a high risk for DALYs associated with a high body-mass index. The projected trend indicates a surge in new liver cancer incident cases, expected to rise from around 905,347 to an estimated 1,392,474 by 2040. This study described the evidence pertinent to higher incidence trends in liver cancer, particularly among both young and older adults, encompassing males and females, as well as those who are HIV-infected and HBsAg positive. A significant rise in the young population poses a significant public health concern that warrants attention from healthcare professionals to prioritize the promotion of health awareness and the development of effective cancer prevention strategies, particularly in many developing countries.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou, People’s Republic of China (GRID:grid.412633.1)
2 The First Affiliated Hospital of Zhengzhou University, Department of Radiation Oncology and Cancer Center, Zhengzhou, People’s Republic of China (GRID:grid.412633.1); The First Affiliated Hospital of Zhengzhou University, Cancer Center, Zhengzhou, People’s Republic of China (GRID:grid.412633.1)
3 Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Chiyyedu, India (GRID:grid.412633.1); Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Department of Pediatrics, Indianapolis, USA (GRID:grid.412633.1) (ISNI:0000 0001 2296 1126); Department of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation (GRID:grid.448878.f) (ISNI:0000 0001 2288 8774); University of Mysore, Department of Studies in Molecular Biology, Mysore, India (GRID:grid.413039.c) (ISNI:0000 0001 0805 7368)
4 The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou, People’s Republic of China (GRID:grid.412633.1); The First Affiliated Hospital of Zhengzhou University, Department of Radiation Oncology and Cancer Center, Zhengzhou, People’s Republic of China (GRID:grid.412633.1)
5 JSS Academy of Higher Education and Research (JSS AHER), Department of Pulmonary Medicine, JSS Medical College, Mysuru, India (GRID:grid.411962.9) (ISNI:0000 0004 1761 157X)
6 Department of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation (GRID:grid.448878.f) (ISNI:0000 0001 2288 8774)